Spyre Therapeutics, INC 8-K filings

Spyre Therapeutics exchanged 90,992 shares of Series A Preferred Stock for 3,639,680 shares of common stock with an existing stockholder.

Spyre Therapeutics has successfully raised approximately $180 million through a private placement to fund its inflammatory bowel disease (IBD) pipeline and extend its cash runway.

Spyre Therapeutics reported its fourth quarter and full year 2023 financial results, highlighted by a $180 million private placement and progress in its IBD pipeline.

Spyre Therapeutics implements a new code of business conduct and ethics, appoints Mark McKenna to its board of directors, and amends CEO Cameron Turtle's employment agreement.

Spyre Therapeutics has received approval to transfer its stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective January 19, 2024.